Whilst visiting Berlin in late November / early December 2019, MD/PhD student Yoshikazu Chishiki from Chiba was introduced to specific analytical processes developed by the Berlin lab to quantify brain and spinal cord subvolumes, which ought to be applied on MR-images of patients from Chiba to complement the joint Japanese-German database. Mr. Chishiki works on a project extracting regional differences in classical and novel MRI-parameters of MS and NMOSD patients from Germany and Japan: an intriguing subproject of the multimodal MRI-study.
To celebrate the 10 year collaboration between Charité and Chiba Universities, Japanese ambassador Takeshi Yagi invited members of both institutions on October 23rd to a symposium with a subsequent reception at the Japanese embassy in Berlin. The important role of CCC-Neuro for the collaboration between both institutions was highlighted in presentations by Chiba University Vice president Dr. Haruaki Nakaya, Professor Chisato Mori, the initiator of the Charité-Chiba cooperation, and Charité dean Professor Axel Radlach Pries. To our delight, CCC-Neuro member Karen Otte also had the opportunity to report on her research stay in Prof. Kuwabara’s team at Chiba University for the JSPS summer programme 2018.
On behalf of CCC-Neuro, Friedemann Paul and Hanna Zimmermann organized a joint Japanese-German Workshop about “Neurological disorders: Risk factors, prevention and prognosis” in Berlin.
On the 23rd and 24th October 2019, students and lecturers from Chiba University in Japan and Charité University in Berlin joined the workshop to learn about the increasing global burden of neurological disorders and the latest diagnostic and therapeutic approaches.
Graham Cooper, a PhD Fellow from Berlin, enjoyed a productive summer working with colleagues in the CCC-Neuro laboratory. He established an automatic analysis pipeline to calculate the standardized T1w/T2w ratio using clinical MRI data. This data was then used to evaluate normal appearing white matter damage in Japanese patients with multiple sclerosis, neuromyelitis optica spectrum disorders and multiple system atrophy, previously unable to be investigated without advanced imaging protocols which are not typically available in the clinical routine.